Constituent yields and biomarkers of exposure for tobacco product regulation

烟草产品监管的成分产量和暴露生物标志物

基本信息

  • 批准号:
    8729472
  • 负责人:
  • 金额:
    $ 40.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-09-02 至 2018-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): A mandated reduction in cigarette smoke of selected carcinogens and toxicants has been recommended by the World Health Organization Study Group on Tobacco Product Regulation (TobReg) and is now possible in the U.S. under the Family Smoking Prevention and Tobacco Control Act. Although a mandated reduction of individual toxicants and carcinogens may not necessarily lead to reduction in health risks, some potent carcinogens in cigarette smoke can be substantially reduced by modifying cigarette manufacturing approaches. Therefore, the overall goal would be to progressively reduce levels of these constituents in mainstream smoke as measured by standardized machine determined methods. However, the issue of how to test and regulate the contents of cigarette smoke represents a critical challenge. The currently used standard machine testing methods do not account for the complexities of smoker-cigarette interaction and are widely recognized to be inadequate for the prediction of human exposures. TobReg study group recommended that levels of toxicants be established per mg of nicotine. However, it is not known how the constituent per mg nicotine emissions in cigarette smoke are related to individual constituent exposures in smokers, and which factors may affect this relationship. Moreover, it is not clear which of the traditionally used standard smoking machine regimens may deliver constituent per mg nicotine levels in the U.S. cigarettes that are most closely related to the smokers' exposure. The goal of our proposal is to address these critical gaps. Building on our expertise in the analysis of tobacco products and biomarkers of exposure, we will focus on the carcinogenic tobacco-specific nitrosamines N2-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) to conduct research as described in the following specific aims: (1) To examine NNN and NNK per mg nicotine emissions in various U.S. cigarette brands under different smoking regimens. (2) To examine the extent to which changes in NNN and NNK per mg nicotine yields in smoke succeed in predicting changes in smokers' exposure to these carcinogens. (3) To determine which individual factors (for example, duration and intensity of smoking, nicotine metabolism, demographics) may affect the relationship between the machine- measured TSNA per mg nicotine and exposures in smokers. These factors may need to be considered when examining constituent/mg nicotine smoke yields for regulatory purposes. This research is critical for expanding the science base that informs the FDA as it develops, evaluates, and implements tobacco product regulations.
描述(由申请人提供):世界卫生组织烟草产品法规研究小组(TobReg)建议强制减少香烟烟雾中的选定致癌物和有毒物,根据《家庭吸烟预防和烟草控制法》,美国现在可以这样做。虽然强制减少个别有毒物质和致癌物质可能不一定会导致健康风险的减少,但通过改变卷烟制造方法,可以大大减少卷烟烟雾中的一些强致癌物质。因此,总体目标将是逐步降低主流烟气中这些成分的水平,如通过标准化机器确定的方法所测量的。然而,如何测试和调节香烟烟雾的含量是一个关键的挑战。目前使用的标准机器测试方法没有考虑到吸烟者-香烟相互作用的复杂性,并且被广泛认为不足以预测人体暴露。TobReg研究小组建议确定每毫克尼古丁的有毒物质水平。然而,目前尚不清楚香烟烟雾中每毫克尼古丁排放的成分与吸烟者个体成分暴露量之间的关系,以及哪些因素可能影响这种关系。此外,目前尚不清楚传统使用的标准吸烟机方案中的哪一种可以在美国香烟中提供与吸烟者的暴露最密切相关的每mg尼古丁水平的成分。我们提案的目标是解决这些关键差距。基于我们在烟草产品和暴露生物标志物分析方面的专业知识,我们将重点关注致癌烟草特有的亚硝胺N2-亚硝基去甲烟碱(NNN)和4-亚硝基去甲烟碱。1-甲基亚硝胺(3-吡啶基)-1-丁酮(NNK)进行研究,具体目标如下:(1)研究在不同吸烟方案下,各种美国香烟品牌每毫克尼古丁的NNN和NNK排放量。(2)检查NNN和NNK/mg尼古丁含量的变化在多大程度上成功预测了吸烟者暴露于这些致癌物的变化。(3)确定哪些个体因素(例如,吸烟持续时间和强度、尼古丁代谢、人口统计学)可能影响机器测量的TSNA/mg尼古丁与吸烟者暴露量之间的关系。出于监管目的,在检查成分/mg尼古丁烟雾量时,可能需要考虑这些因素。这项研究对于扩大FDA制定、评估和实施烟草产品法规的科学基础至关重要。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Irina Stepanov其他文献

Irina Stepanov的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Irina Stepanov', 18)}}的其他基金

Core B: Biomarker and Constituent Core
核心 B:生物标志物和核心成分
  • 批准号:
    10246924
  • 财政年份:
    2017
  • 资助金额:
    $ 40.81万
  • 项目类别:
Nornicotine in smokeless tobacco as a precursor for carcinogen exposure
无烟烟草中的去甲尼古丁是致癌物质暴露的前体
  • 批准号:
    9477430
  • 财政年份:
    2014
  • 资助金额:
    $ 40.81万
  • 项目类别:
Constituent yields and biomarkers of exposure for tobacco product regulation
烟草产品监管的成分产量和暴露生物标志物
  • 批准号:
    8574995
  • 财政年份:
    2013
  • 资助金额:
    $ 40.81万
  • 项目类别:
Constituent yields and biomarkers of exposure for tobacco product regulation
烟草产品监管的成分产量和暴露生物标志物
  • 批准号:
    9121508
  • 财政年份:
    2013
  • 资助金额:
    $ 40.81万
  • 项目类别:
Core B: Biomarker and Constituent Core
核心 B:生物标志物和核心成分
  • 批准号:
    9567953
  • 财政年份:
  • 资助金额:
    $ 40.81万
  • 项目类别:
Core B: Biomarker and Constituent Core
核心 B:生物标志物和核心成分
  • 批准号:
    9358860
  • 财政年份:
  • 资助金额:
    $ 40.81万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 40.81万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 40.81万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.81万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.81万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 40.81万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.81万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 40.81万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 40.81万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 40.81万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.81万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了